Want to see DE:MED full AI Analyst Report?
Top Page
MEDICLIN
(XETRA:MED)
Select Model
Select Model
Rating:63Neutral
Price Target:
€4.50
▲(25.00% Upside)
Action:Reiterated
Date:05/22/26
The score is driven primarily by improving financial performance and solid cash generation, tempered by balance-sheet risk from elevated leverage and a history of margin volatility. Technicals are mildly supportive with neutral momentum, and valuation looks reasonable at a ~12x P/E with a modest dividend.
Positive Factors
Improving Revenue & Profitability
Sustained TTM revenue growth of ~26% with a return to positive EBIT and net margins indicates recovering demand and improving operational execution. Over 2–6 months this supports steady cash generation, better coverage of fixed costs, and greater resilience versus prior loss periods.
Negative Factors
Elevated Leverage
A TTM debt-to-equity near 1.46x leaves the capital structure relatively debt-heavy, restricting strategic flexibility. Higher leverage raises refinancing and interest-rate sensitivity risks and means shocks to earnings could quickly strain covenants or cash available for investments and dividends.
Read all positive and negative factors
Positive Factors
Negative Factors
Improving Revenue & Profitability
Sustained TTM revenue growth of ~26% with a return to positive EBIT and net margins indicates recovering demand and improving operational execution. Over 2–6 months this supports steady cash generation, better coverage of fixed costs, and greater resilience versus prior loss periods.
Read all positive factors
MEDICLIN (MED) vs. iShares MSCI Germany ETF (EWG)
Market Cap
€191.90M
Dividend Yield1.12%
Average Volume (3M)5.25K
Price to Earnings (P/E)6.8
Beta (1Y)0.21
Revenue Growth5.13%
EPS Growth11.89%
CountryDE
Employees7,292
SectorGeneral
Sector StrengthN/A
IndustryMedical - Care Facilities
Share Statistics
EPS (TTM)0.60
Shares Outstanding47,500,000
10 Day Avg. Volume4,347
30 Day Avg. Volume5,253
Financial Highlights & Ratios
PEG Ratio1.78
Price to Book (P/B)0.71
Price to Sales (P/S)0.22
P/FCF Ratio3.42
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)0.78
Revenue Forecast (FY)€805.60M
MEDICLIN Business Overview & Revenue Model
Company Description
Mediclin AG is a German healthcare enterprise primarily engaged in managing hospitals across the nation. Its operations are categorized into three main segments: Post-Acute, Acute, and various other related activities. The company offers a compreh...
How the Company Makes Money
MEDICLIN makes money primarily by delivering healthcare services through its facilities and receiving reimbursement from payers. Key revenue streams typically include: (1) Acute care (hospitals/clinics): revenue generated from inpatient and outpat...
MEDICLIN Financial Statement Overview
Summary
Income Statement
68
Positive
Balance Sheet
52
Neutral
Cash Flow
63
Positive
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Mar 2023 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 786.53M | 784.49M | 748.80M | 730.10M | 704.70M | 673.10M |
| Gross Profit | 119.11M | 113.81M | 623.00M | 594.60M | 571.90M | 551.00M |
| EBITDA | 42.54M | 98.66M | 106.41M | 101.27M | 91.80M | 85.43M |
| Net Income | 29.18M | 25.49M | 24.84M | -10.78M | 9.44M | 1.46M |
Balance Sheet | ||||||
| Total Assets | 835.90M | 879.69M | 905.91M | 880.50M | 916.11M | 881.24M |
| Cash, Cash Equivalents and Short-Term Investments | 152.40M | 72.18M | 107.56M | 115.29M | 88.04M | 133.48M |
| Total Debt | 384.07M | 390.83M | 464.13M | 479.82M | 502.67M | 439.96M |
| Total Liabilities | 582.73M | 630.06M | 683.17M | 684.47M | 706.79M | 698.22M |
| Stockholders Equity | 252.47M | 248.95M | 222.51M | 195.92M | 209.21M | 183.28M |
Cash Flow | ||||||
| Free Cash Flow | 48.68M | 51.44M | 35.88M | 40.43M | 8.62M | 64.96M |
| Operating Cash Flow | 93.98M | 99.87M | 80.57M | 78.00M | 34.64M | 81.97M |
| Investing Cash Flow | -23.66M | -37.14M | -15.13M | -9.51M | -6.24M | -7.09M |
| Financing Cash Flow | -96.37M | -97.40M | -73.16M | -45.48M | -56.17M | -55.26M |
MEDICLIN Technical Analysis
Positive
3.60
Price Trends
3.84
Positive
3.69
Positive
3.62
Positive
Market Momentum
0.04
Positive
57.61
Neutral
66.67
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For DE:MED, the sentiment is Positive. The current price of 3.6 is below the 20-day moving average (MA) of 4.02, below the 50-day MA of 3.84, and below the 200-day MA of 3.62, indicating a bullish trend. The MACD of 0.04 indicates Positive momentum. The RSI at 57.61 is Neutral, neither overbought nor oversold. The STOCH value of 66.67 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for DE:MED.
MEDICLIN Peers Comparison
UnderperformOutperform
Sector (55)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
82 Outperform | €344.42M | 16.03 | 18.60% | 2.80% | 7.40% | 38.17% | |
74 Outperform | €162.00M | 27.99 | 24.05% | ― | 33.49% | 81.79% | |
63 Neutral | €191.90M | 6.76 | 11.90% | 1.12% | 5.13% | 11.89% | |
57 Neutral | €937.14M | 23.17 | 3.04% | 0.77% | 6.06% | 0.93% | |
55 Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% | |
45 Neutral | €19.08M | -1.27 | 21.40% | ― | 3.53% | -5.29% |
* General Sector Average
DE:MED
MEDICLIN
4.04
1.11
37.98%
DE:RHK
RHON-KLINIKUM AG
13.50
1.59
13.39%
DE:MAK
MATERNUS-Kliniken AG
0.97
-0.15
-13.39%
DE:LIK
Limes Schlosskliniken AG
540.00
177.05
48.78%
DE:JTH0
Gesundheitswelt Chiemgau AG
10.00
-2.08
-17.23%
DE:M12
M1 Kliniken AG
18.10
4.85
36.56%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.